The average level of ADAM9 mRNA in stage IV bladder cancer patients was significantly higher than patients in stages I, II, and III (3094.24 vs. 2083.05, 2302, 2403.38, respectively) (p = 0.014) (Figure 6A). This evidence concerns the gene ADAM9 and urinary bladder carcinoma.